Plus Therapeutics, Inc. (PSTV)
Largest Insider Buys in Sector
PSTV Stock Price History Chart
PSTV Stock Performance
About Plus Therapeutics, Inc.
Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer and other diseases. Its lead drug candidate is Rhenium-186 NanoLiposome, a patented radiotherapy that targets central nervous system cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. It has a license agreement with NanoTx, Corp. to develop and commercialize NanoTx's glioblastoma treatment. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas.
Insider Activity of Plus Therapeutics, Inc.
Over the last 12 months, insiders at Plus Therapeutics, Inc. have bought $181,784 and sold $4,053 worth of Plus Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Plus Therapeutics, Inc. have bought $79,088 and sold $2,262 worth of stock each year.
Highest buying activity among insiders over the last 12 months: Petersen Greg (director) — $177,187. Lenk Robert P (director) — $47,700. Clowes Howard (director) — $30,022.
The last purchase of 12,255 shares for transaction amount of $25,000 was made by Petersen Greg (director) on 2024‑05‑08.
List of Insider Buy and Sell Transactions, Plus Therapeutics, Inc.
| 2024-05-08 | Petersen Greg | director | 12,255 0.2576% | $2.04 | $25,000 | -4.85% | ||
| 2024-05-08 | Lenk Robert P | director | 4,167 0.0876% | $2.04 | $8,501 | -4.85% | ||
| 2024-05-08 | Clowes Howard | director | 9,804 0.206% | $2.04 | $20,000 | -4.85% | ||
| 2024-05-08 | HEDRICK MARC H | Chief Executive Officer | 12,255 0.2576% | $2.04 | $25,000 | -4.85% | ||
| 2024-05-08 | Sims Andrew John Hugh MacIntyre | Chief Financial Officer | 4,902 0.103% | $2.04 | $10,000 | -4.85% | ||
| 2024-05-08 | Hawkins Richard J | director | 4,902 0.103% | $2.04 | $10,000 | -4.85% | ||
| 2023-11-20 | Sale | HEDRICK MARC H | Chief Executive Officer | 2,068 0.0487% | $1.96 | $4,053 | +7.22% | |
| 2023-11-16 | Lenk Robert P | director | 1,000 0.02% | $1.95 | $1,950 | -11.87% | ||
| 2023-11-15 | Lenk Robert P | director | 1,000 0.0206% | $1.77 | $1,770 | +3.21% | ||
| 2023-11-13 | Lenk Robert P | director | 4,000 0.086% | $1.43 | $5,720 | +31.29% | ||
| 2023-11-10 | Lenk Robert P | director | 2,000 0.0452% | $1.45 | $2,900 | +37.37% | ||
| 2023-11-09 | Lenk Robert P | director | 4,199 0.0971% | $1.59 | $6,676 | +29.36% | ||
| 2023-11-08 | Lenk Robert P | director | 5,000 0.1147% | $1.65 | $8,250 | +21.07% | ||
| 2023-11-07 | Lenk Robert P | director | 6,000 0.1303% | $1.64 | $9,840 | +16.36% | ||
| 2023-11-06 | Lenk Robert P | director | 1,395 0.0286% | $1.50 | $2,093 | +19.25% | ||
| 2023-09-13 | Clowes Howard | director | 6,993 0.2417% | $1.43 | $10,022 | +30.07% | ||
| 2023-09-11 | Petersen Greg | director | 20,000 0.7886% | $1.70 | $34,062 | +23.67% | ||
| 2023-06-06 | Clowes Howard | director | 1,000 0.003% | $3.98 | $3,980 | -48.40% | ||
| 2023-05-03 | Clowes Howard | director | 2,500 0.007% | $3.64 | $9,102 | -48.27% | ||
| 2023-03-03 | Hawkins Richard J | director | 1 – | $1,000.00 | $1,000 | -59.05% |
Insider Historical Profitability
| Lenk Robert P | director | 29327 0.5563% | $1.47 | 11 | 1 | <0.0001% |
| Petersen Greg | director | 36421 0.5343% | $1.47 | 6 | 0 | <0.0001% |
| Sims Andrew John Hugh MacIntyre | Chief Financial Officer | 5717 0.2704% | $1.47 | 7 | 0 | <0.0001% |
| Clowes Howard | director | 21497 0.2585% | $1.47 | 6 | 0 | <0.0001% |
| HEDRICK MARC H | Chief Executive Officer | 12425 0.0038% | $1.47 | 27 | 2 | <0.0001% |
| Hawkins Richard J | director | 4903 0% | $1.47 | 2 | 0 | <0.0001% |
| Lim Kian Thiam | 10 percent owner | 7400000 163.6205% | $1.47 | 0 | 1 | |
| Swissquote Bank SA | 10 percent owner | 5328229 117.8118% | $1.47 | 0 | 3 | |
| PostFinance AG | 10 percent owner | 4543086 100.4516% | $1.47 | 0 | 5 | |
| OLYMPUS CORP | 10 percent owner | 4013043 88.7319% | $1.47 | 2 | 0 | |
| Saad Mark E | Chief Financial Officer | 152500 3.3719% | $1.47 | 16 | 0 | |
| CALHOUN CHRISTOPHER J | Chief Executive Officer | 118125 2.6118% | $1.47 | 8 | 21 | |
| Girao Tiago | VP & Chief Financial Officer | 88000 1.9458% | $1.47 | 3 | 0 | |
| Thompson Tommy G | director | 83600 1.8485% | $1.47 | 3 | 0 | |
| HAWRAN PAUL W | director | 71610 1.5834% | $1.47 | 8 | 0 | |
| HENRIKSEN RONALD D | director | 60092 1.3287% | $1.47 | 5 | 1 | |
| RICKEY DAVID | director | 55226 1.2211% | $1.47 | 32 | 0 | |
| Dean Lloyd H | director | 40000 0.8844% | $1.47 | 4 | 0 | |
| HOLMES E CARMACK | director | 27401 0.6059% | $1.47 | 1 | 1 | |
| HAYDEN JEREMY B. | General Counsel & VP of BD | 26200 0.5793% | $1.47 | 2 | 0 | |
| SHIRAHAMA NORIO SEIJIRO | President - Asia Pacific | 10200 0.2255% | $1.47 | 5 | 0 | |
| HARRIS JOHN DAVID | VP and GM Cell Therapy | 7000 0.1548% | $1.47 | 2 | 0 | |
| KESTEN STEVEN | Exec VP and Chief MO | 6000 0.1327% | $1.47 | 1 | 0 | |
| COX MARSHALL G | director | 3934 0.087% | $1.47 | 0 | 9 | |
| Naughton Gail K | director | 2400 0.0531% | $1.47 | 1 | 0 | |
| Milstein Alexander M | Vice President Clinical Develo | 1200 0.0265% | $1.47 | 4 | 0 |
Institutional Investor Ownership
No records found… | |||||||